Alfasigma Completes Agreement with GSK for linerixibat
Alfasigma S.p.A., a global pharmaceutical company, today announced the completion of its previously announced licence agreement with GSK plc....
Read more
Alfasigma Streamlines Manufacturing Footprint to Sharpen Strategic Focus and Accelerate Innovation and Growth
Alfasigma, a global pharmaceutical company headquartered in Italy, today announced that it has entered into an agreement for the sale of 100% of the share capital of its subsidiary Sofar S.p.A. (“So...
Read more
Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%)[1], Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets.
Alfasigma S.p.A (“Alfasigma” or the “Company”), a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered, today announced its financial results for the fis...
Read more
Linerixibat approved for use in the U.S. for the treatment of cholestatic pruritus in primary biliary cholangitis (PBC)
Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, welcomes today’s decision of the U.S. Food and Drug Administration (FDA) to approve linerixibat for the treatment of cholestatic ...
Read more
GSK and Alfasigma announce agreement on worldwide rights for linerixibat
GSK plc (LSE/NYSE: GSK) and Alfasigma S.p.A. today announced a licence agreement under which Alfasigma will acquire worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an...
Read more
Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease
Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, and Innovative Molecules GmbH (“Innovative Molecules”), a clinical-stage biotechnology company, today announced a strategic par...
Read more
Filgotinib Shows Positive Topline Results Across Full Spectrum of Axial Spondyloarthritis in OLINGUITO Phase 3 Study
Alfasigma S.p.A today announced positive topline results from the OLINGUITO Phase 3 clinical trial (NCT05785611; Eudra CT 2022-501354-10-01),[i] evaluating filgotinib (marketed as Jyseleca® in approv...
Read more
Alfasigma Reports Record Growth in First-Ever Financial Results; €1.87 billion Revenue Setting the Stage for Future Growth
Alfasigma S.p.A (“Alfasigma” or the “Company”), a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered, today announced its financial results for the fis...
Read more
Alfasigma announces the Completion of Marketing Authorisation Transfer for Jyseleca® in the European Union
• Following a positive opinion from the EMA, the transfer of marketing authorization of Jyseleca from Galapagos NV to Alfasigma S.p.A has been approved by the European Commission. • Alfasigma S....
Read more
M&A for growth, 20 years of M&A in Italy, the best deals of 2023
Alfasigma S.p.A has been selected as a finalist in the 20th edition of the M&A Awards: 20 Years of M&A in Italy, The Best Deals Of 2023, the initiative promoted by KPMG and Fineurop Soditic Spa, with ...
Read more